Distribution of selected variables between the gastric cancer cases and control subjects.

a<p>Two-sided t-test for difference between the cases and controls.</p>b<p>Two-sided χ² test for distribution between the cases and controls.</p

Association between the <i>APE1</i> T1349G polymorphism and clinicopathologic characteristics of gastric cancer risk.

a<p>Adjusted for age, sex, smoking, and alcohol status in logistic regression model.</p

Begg's funnel plot of publication bias test.

<p>(A) PFS; (B) OS. Each point represents a separate study for the indicated association. Log (OR), natural logarithm of OR. Horizontal line, mean effect size.</p

Hazard ratios, <i>P</i> value, and heterogeneity for ORR and DCR in the stratified analyses.

<p>HR, hazard ratio; <i>P</i>_H, heterogeneity <i>P</i>; GC, gastric cancer; CRC, colorectal cancer; ORR, objective response rate; DCR, disease control rate; RCT, randomized controlled trial; RS, Retrospective study.</p

Fixed-effects model of hazard ratio (95% confidence interval) of PFS associated with S-1-based therapy compared with capecitabine-based therapy.

<p>Fixed-effects model of hazard ratio (95% confidence interval) of PFS associated with S-1-based therapy compared with capecitabine-based therapy.</p

Fixed-effects model of hazard ratio (95% confidence interval) of DCR associated with S-1-based therapy compared with capecitabine-based therapy.

<p>Fixed-effects model of hazard ratio (95% confidence interval) of DCR associated with S-1-based therapy compared with capecitabine-based therapy.</p

Characteristics of literatures included in the meta-analysis.

<p>GC, gastric cancer; CRC, colorectal cancer; OS, overall survival; PFS, progression-free survival; RCT: randomized controlled trial; S, S−1; C, capecitabine.</p

Hazard ratios, <i>P</i> value, and heterogeneity for PFS and OS in the stratified analyses.

<p>HR, hazard ratio; <i>P</i>_H, heterogeneity <i>P</i>; GC, gastric cancer; CRC, colorectal cancer; OS, overall survival; PFS, progression-free survival; RCT, randomized controlled trial; RS, Retrospective study;</p

Fixed-effects model of hazard ratio (95% confidence interval) of OS associated with S-1-based therapy compared with capecitabine-based therapy.

<p>Fixed-effects model of hazard ratio (95% confidence interval) of OS associated with S-1-based therapy compared with capecitabine-based therapy.</p

Fixed-effects model of hazard ratio (95% confidence interval) of ORR associated with S-1-based therapy compared with capecitabine-based therapy.

<p>Fixed-effects model of hazard ratio (95% confidence interval) of ORR associated with S-1-based therapy compared with capecitabine-based therapy.</p